Xiayang Qiu
Founder and CEO,
Regor Therapeutics
Dr. Xiayang Qiu, founder and CEO of Regor Therapeutics Group, has a remarkable track record in structure-based drug design across therapeutic areas and modalities. The Regor Computer Accelerated Rational Discovery – rCARD – technology platform he established with his cofounders has already delivered the unique CDK4+ inhibitor RGT-419B, recently in-licensed by Roche for $850M up-front + milestones, and the leading oral small molecule GLP-1R full agonist RGT-075 for obesity and other metabolic diseases. Regor also has pipeline candidates focused on other prominent targets and particular unmet needs (STING, HPK and others).
Before founding Regor, Dr. Qiu built and led industry-leading teams in structural and molecular sciences and established the first high-resolution cryo-EM laboratory in US biopharma. He is the inventor of the blockbuster RSV vaccine Abrysvo, the first-ever vaccine approved for maternity immunization to prevent infant infections. Dr. Qiu graduated from Peking University and received his PhD from Michigan State University. He was an NIH postdoctoral fellow at the University of Washington and is the author of over 60 publications (8,000 citations) and a dozen patents. He has trained 15 postdocs and served on multiple expert review panels for the US National Institutes of Health.
Suffix
PhD
Sessions
-
10-Feb-2025Obesity: Next Medicines with Impact
)
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}